Combustion-Generated EPFRs: Assessing Cardiovascular Risks of Exposure
燃烧产生的 EPFR:评估暴露的心血管风险
基本信息
- 批准号:10576461
- 负责人:
- 金额:$ 28.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-15 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAgonistAirAirborne Particulate MatterAlveolarArchivesAryl Hydrocarbon ReceptorBindingBiological MarkersBloodBlood PressureBlood VesselsCardiacCardiopulmonaryCardiovascular DiseasesCardiovascular systemCathetersCollaborationsCommunitiesComplementDataData AnalysesDevelopmentDevicesEndothelial CellsEndotheliumEnvironmentEpithelial CellsEpitheliumExposure toFree RadicalsFunctional disorderHazardous WasteHealthHeartHeart DiseasesHistologyIndustrializationInhalationInhalation ExposureInhalation ToxicologyInjuryKnowledgeLeftLeft Ventricular FunctionLigandsLinkLipidsLungMass Spectrum AnalysisMeasuresMediatingMediatorMembraneMembrane LipidsModelingMorphologyMusMyocardial dysfunctionOxidation-ReductionOxidative StressParticulate MatterPhysiologic intraventricular pressurePhysiologicalPlayPulmonary Vascular ResistanceReactive Oxygen SpeciesReceptor ActivationResearchRiskRisk AssessmentRodentRoleSecondary toSignal Recognition ParticleSiteSoilSourceSuperfundSystemTechnologyTelemetryTestingTissuesToxic effectVascular DiseasesVentricularWorkair filteralveolar epitheliumaryl hydrocarbon receptor ligandbiological systemsbody systemcardiovascular risk factordata managementdesignendothelial dysfunctionenvironmental chemistryepidemiologic datafree radical oxygenheart functionlung pressuremortalitynoveloxidationoxidized lipidparticlepollutantpressurepulmonary arterial pressureremediationresponsesmall moleculesuperfund siteuptakevascular injuryweb portal
项目摘要
Project Summary/Abstract: Project 2
Particulate matter (PM) is consistently associated with cardiopulmonary and cardiovascular mortality. Despite
the risk of exposure, little is known about the mechanisms underlying PM-mediated toxicity. Our Center has
shown that PM emissions from the thermal treatment (TT) of hazardous organics or contaminated soils at
Superfund sites produce environmentally persistent free radicals (EPFRs). EPFRs are a unique particle-
pollutant system capable of redox cycling to generate reactive oxygen species (ROS) in biological systems.
EPFRs are present in contaminated Superfund soils and airborne PM near industrialized Superfund sites. Our
prior Superfund project focused on the role of EPFRs in modulating cardiac function and disease. Although
inhalation of EPFRs decreased baseline cardiac function, we found that these effects were secondary to
changes in pulmonary vascular resistance. The mechanism(s) underlying these vascular effects are unknown;
however, our preliminary data suggest that EPFR-mediated activation of the aryl hydrocarbon receptor (AhR)
in pulmonary epithelial cells resulting in the release of vasoactive factors may play an important
pathophysiological role. Our central hypothesis is that EPFR-mediated activation of AhR at the air-blood
interface and mobilization of vasoactive mediators leads to activation/dysfunction of the pulmonary and
systemic vasculature, resulting in cardiovascular disease. To test this hypothesis, Specific Aim 1 will test
whether EPFR-mediated activation of the AhR in lung epithelium is responsible for the increase in pulmonary
pressure and decreased diastolic filling that underlies EPFR induced cardiac dysfunction. After establishing the
vasculature as the locus of injury, Specific Aim 2 will elucidate the cellular mechanisms of vascular injury by
testing whether EPFRs induce vascular dysfunction via activation of the AhR. In both aims, control littermate
mice and mice deficient in AhR specifically in alveolar type II will be exposed subchronially to EPFRs, non-
EPFR PM, or filtered air using a recently designed inhalation system. Millar pressure-volume catheters will be
used to measure left ventricular function and pulmonary arterial pressure in exposed mice. Telemetry devices
will be used to record blood pressure. Endothelium-dependent vascular reactivity, as well as markers for both
endothelial dysfunction and activation, will be assessed. Specific Aim 3 will identify a putative ligand promoting
EPFR-induced AhR activation and test whether this metabolite is associated with EPFR-mediated vascular
dysfunction. In collaboration with Project 1, this aim will use novel mass spectrometry approaches to identify
and characterize EPFR-induced lipid oxidation products that may serve as endogenous AhR agonists so that
we may correlate tissue and blood levels of these metabolites with vascular dysfunction. Completion of these
Aims will provide important new data linking EPFR-mediated oxidative stress in epithelial cells, AhR activation,
and cardiovascular disease. This information is critical for assessing risks to those living in proximity to sites
using TT technologies to remediate Superfund or other hazardous wastes.
项目摘要/摘要:项目2
颗粒物(PM)一直与心肺和心血管疾病的死亡率有关。尽管
关于暴露的风险,人们对PM介导的毒性的潜在机制知之甚少。我们的中心有
结果表明,有害有机物或受污染土壤的热处理(TT)产生的PM排放
超级基金网站产生环境持久性自由基(EPFR)。EPFR是一种独特的粒子-
能够在生物系统中进行氧化还原循环以产生活性氧物种(ROS)的污染物系统。
EPFR存在于受污染的超级基金土壤和工业化超级基金场地附近的空气PM中。我们的
之前的超级基金项目侧重于EPFR在调节心脏功能和疾病中的作用。虽然
吸入EPFR会降低基础心功能,我们发现这些影响是继发性的
肺血管阻力的变化。这些血管效应背后的机制(S)尚不清楚;
然而,我们的初步数据表明,EPFR介导的芳烃受体(AhR)激活
在肺上皮细胞中导致血管活性因子的释放可能起重要作用
病理生理作用。我们的中心假设是EPFR介导的AhR在空气-血液中的激活
血管活性物质的界面和动员导致肺和肺功能的激活/功能障碍
全身血管系统,导致心血管疾病。为了验证这一假设,《特定目标1》将测试
EPFR介导的肺上皮细胞AhR激活是否与肺活量增加有关
压力和舒张期充盈减少是EPFR引起的心功能不全的基础。在建立了
血管系统作为损伤的部位,特异靶2将通过以下方式阐明血管损伤的细胞机制
测试EPFR是否通过激活AhR而导致血管功能障碍。在这两个目标中,控制产仔
小鼠和AHR缺陷的小鼠,特别是在肺泡II型上,将亚慢性暴露于EPFR,非
EPFR PM,或使用最近设计的吸入系统过滤的空气。米勒压力-容量导管将是
用于测量暴露小鼠的左心功能和肺动脉压。遥测设备
将被用来记录血压。内皮依赖性血管反应性以及两者的标志物
将对内皮功能障碍和激活情况进行评估。具体目标3将确定一个假定的配体促进
EPFR诱导的AhR激活并检测该代谢物是否与EPFR介导的血管相关
功能障碍。与项目1合作,这一目标将使用新的质谱学方法来确定
并鉴定EPFR诱导的可能作为内源性AhR激动剂的脂质氧化产物,从而
我们可能会将这些代谢物的组织和血液水平与血管功能障碍联系起来。完成这些工作
AIMS将提供重要的新数据,将EPFR介导的上皮细胞氧化应激,AhR激活,
和心血管疾病。这些信息对于评估居住在工地附近的人的风险至关重要。
使用TT技术修复超级基金或其他危险废物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TAMMY R DUGAS其他文献
TAMMY R DUGAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TAMMY R DUGAS', 18)}}的其他基金
Novel coatings releasing synergistic polyphenols promote vascular healing
新型涂层释放协同多酚促进血管愈合
- 批准号:
8716232 - 财政年份:2014
- 资助金额:
$ 28.87万 - 项目类别:
Novel coatings releasing synergistic polyphenols promote vascular healing
新型涂层释放协同多酚促进血管愈合
- 批准号:
8918078 - 财政年份:2014
- 资助金额:
$ 28.87万 - 项目类别:
Research Experience and Training Coordination Core (RETCC)
研究经验和培训协调核心(RETCC)
- 批准号:
10341189 - 财政年份:2009
- 资助金额:
$ 28.87万 - 项目类别:
Combustion-Generated EPFRs: Assessing Cardiovascular Risks of Exposure
燃烧产生的 EPFR:评估暴露的心血管风险
- 批准号:
10341193 - 财政年份:2009
- 资助金额:
$ 28.87万 - 项目类别:
Antiretroviral Therapy, Endothelial Dysfunction and Atherosclerosis
抗逆转录病毒治疗、内皮功能障碍和动脉粥样硬化
- 批准号:
7838921 - 财政年份:2009
- 资助金额:
$ 28.87万 - 项目类别:
Research Experience and Training Coordination Core (RETCC)
研究经验和培训协调核心(RETCC)
- 批准号:
10576457 - 财政年份:2009
- 资助金额:
$ 28.87万 - 项目类别:
Combustion-Generated EPFRs: Assessing Cardiovascular Risks of Exposure
燃烧产生的 EPFR:评估暴露的心血管风险
- 批准号:
10116407 - 财政年份:2009
- 资助金额:
$ 28.87万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 28.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 28.87万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)